All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.


Application of Programmed Cell Death Protein 1 Inhibitor, Camrelizumab in Advanced Cancer

Author(s): Z. Y. Ding, Tong Jiang, Ying Piao, Juan Chen and Z. D. Zheng*
Department of Oncology, General Hospital of Northern Theater Command, Wenhua, Shenyang 110840, 1Laboratory of Military Health in Cold Region, Center for Disease Control and Prevention of Northern Theater Command, Longshan, Shenyang 110013, China

Correspondence Address:
Z. D. Zheng, Department of Oncology, General Hospital of Northern Theater Command, Wenhua, Shenyang 110840, China, E-mail:

The single use of the programmed cell death protein 1 inhibitor camrelizumab has been studied a lot. However, the comparison of its combined use in various types of advanced lung cancer and whether it has a better application effect has been studied in this experiment and speculate on the immune mechanism after its use. From September 2019 to April 2023 (18 mo including follow-up time), 100 patients with advanced lung cancer treated with camrelizumab were selected and divided into 2 groups according to patient’s interest. 50 patients were divided into camrelizumab (200 mg)+platinum-based chemotherapy as the control group. The 50 patients in the experimental group received camrelizumab (200 mg) and apatinib (250 mg, once/d)+platinum-based chemotherapy. After 2 cycles of treatment, we compared the clinical efficacy of the two groups, observed the adverse drug reactions of the two groups, follow up for 12 mo and observed the progression-free survival time and median survival time of the two groups. In the experimental group the objective response rate=30 % and disease control rate=90 %, and the objective response rate=14 % and disease control rate=40 % in the control group, which means the curative effect of the experimental group was much better than that of the control group (p<0.05). Both groups had some adverse reactions, but they were all in grade 1 or 2 and there was no serious life-threatening (p>0.05). The overall survival time of the control group was 8.44±1.70 mo and the experimental group was 15.78±1.98 mo (p<0.05). The overall survival time of experimental group was slightly longer than that of the control group. Camrelizumab with platinum-based chemotherapy in the control group has a certain application effect. However, camrelizumab with apatinib and platinum-based chemotherapy in the experimental group had better curative effect for patients.

Full-Text | PDF

Google scholar citation report
Citations : 66710

Indian Journal of Pharmaceutical Sciences received 66710 citations as per google scholar report